AstraZeneca’s experimental aldosterone synthase inhibitor baxdrostat demonstrated statistically significant reductions in systolic blood pressure in a phase III trial involving patients with uncontrolled or resistant hypertension. The drug met primary and secondary endpoints and showed a favorable safety profile. These positive results validate AstraZeneca’s $1.3 billion acquisition of CinCor Pharma in 2023. The company anticipates further data presentations and plans regulatory filings to expand treatment options in hypertension.